Comparing blood glucose management methods in LADA patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of a hybrid closed-loop artificial pancreas system compared to a traditional insulin pump combined with Continuous Glucose Monitoring (CGM) in hospitalized patients with Latent Autoimmune Diabetes in Adults (LADA). Conducted at Shanxi Bethune Hospital, the study will enroll 50 LADA patients and randomly assign them to one of the two treatment groups after their admission. The trial will monitor blood glucose levels over a series of 24-hour periods to assess the short-term control effects of each method. The goal is to provide a more personalized blood glucose management plan tailored to the unique needs of LADA patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age between 18 and 70 years old.
2. Meet the diagnostic criteria for LADA in the "Chinese Expert Consensus on the Diagnosis and Treatment of Latent Autoimmune Diabetes in Adults (2021 Edition)":

   * The onset age of diabetes is ≥ 18 years old.
   * Positive for islet autoantibodies or islet autoimmunity T cells.
   * Do not rely on insulin therapy for at least 6 months after the diagnosis of diabetes.
3. Patients are able to correctly use insulin pumps and CGM devices and have a certain learning ability and operational ability.
4. Baseline HbA1c \> 7.0% or HbA1c \> 6.0% combined with hypoglycemia.
5. Patients agree to participate in the study and sign the informed consent form.

Exclusion Criteria:

1. The patient has been clearly diagnosed with type 2 diabetes or special types of diabetes.
2. The patient has experienced acute diabetic complications within the past 1 month, such as diabetic ketoacidosis, hyperglycemic hyperosmolar coma, etc.
3. The patient has severe symptoms of hypoglycemia intolerance.
4. The patient has skin diseases such as rashes and prurigo, or abnormal coagulation function.
5. The patient has diseases related to impaired glucose metabolism, such as uncontrolled hyperthyroidism, hypothyroidism, Cushing's syndrome, etc.
6. The patient has comorbid severe liver, kidney, gastrointestinal, hematological, brain, circulatory system diseases, etc.
7. The patient has other severe chronic diseases (such as malignant tumors, end-stage organ failure, etc.).
8. The patient has impaired consciousness or mental illness, lacks self-control, and cannot express clearly.
9. Lactating women, pregnant women, or women who plan to become pregnant during the trial period.
10. The patient is currently using or has used glucocorticoids or other drugs that interfere with glucose metabolism within 1 month before screening.
11. The patient is allergic to the drugs involved in the clinical diagnosis and treatment plan.
12. The patient is currently using other closed-loop systems.
13. People who are not suitable for conventional insulin pump treatment and those with contraindications.
14. The patient is known or suspected to have an insulin-allergic constitution and is allergic to adhesive tape, insulin pumps, or CGM devices.

Other situations where the researcher deems the patient unfit to participate in the clinical trial.

Where it's running

• Shanxi Bethune Hospital
  Taiyuan, Shanxi, China Recruiting

Study contacts

• Study coordinator: Shiwei Liu, Doctor's degree
• Email: lswspring6@aliyun.com
• Phone: +86 13191072733

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Impact of CT-based 3D printed models on endotracheal intubation success in students

  This study tests whether training with CT-based 3D printed airway models helps students perform endotracheal intubation better than traditional teaching.

  Recruiting Shanxi Bethune Hospital · Taiyuan, Shaanxi · NCT07612995

• Gene patterns that predict response to selinexor for relapsed or refractory multiple myeloma

  We will test if multigene expression patterns can predict how adults with relapsed or refractory multiple myeloma respond to selinexor-based treatment.

  Recruiting Shanxi Bethune Hospital · Taiyuan, Shanxi · NCT07514052

• Epunamin plus DECP for relapsed or refractory multiple myeloma

  This will test whether adding Epunamin to a DECP chemotherapy regimen helps people with relapsed or refractory multiple myeloma have better treatment responses.

  Recruiting Shanxi Bethune Hospital · Taiyuan, Shanxi · NCT07497165

• Integrated Chinese and Western medicine telehealth for long-term diabetes care

  This project will test an online platform that combines Traditional Chinese Medicine and Western medicine to manage adults with type 2 diabetes remotely.

  Recruiting Shanxi Bethune Hospital · Taiyuan, Shanxi · NCT07265037

• Intraosseous infusion for critically ill hematology patients

  This study will test whether intraosseous (through-the-bone) needle infusions provide fast, reliable vascular access for adults 18–65 with severe hematologic conditions in the intensive care setting.

  Recruiting Shanxi Bethune Hospital · Taiyuan, Shanxi · NCT07239375

• Stepwise antibiotic and antifungal treatment for febrile neutropenia in blood cancer patients

  This treatment plan tests whether a stepwise escalation of antibiotics and antifungals can control infection and fever in adults with hematologic malignancies who develop febrile neutropenia.

  Recruiting Shanxi Bethune Hospital · Taiyuan, Shanxi · NCT07204522

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.